Stoke Therapeutics (NASDAQ: STOK) counsel exercises 25,475 RSUs into shares

Rhea-AI Filing Summary

Stoke Therapeutics, Inc. reported that its General Counsel and Corporate Secretary, Jonathan Allan, exercised restricted stock units and acquired common shares. On March 15, 2026, he exercised derivative awards covering 25,475 restricted stock units, each representing one share of common stock, at an exercise price of $0.00 per unit.

These exercises resulted in the acquisition of 25,475 shares of common stock, bringing his directly held common stock position to 37,731 shares following the transactions. Footnotes explain that each RSU converts into one share and that the RSU awards vest in annual installments beginning on March 15, 2024, March 15, 2025, and March 15, 2026, contingent on continued service.

Insider Trade Summary

25,475 shares exercised/converted

Mixed 6 txns

Insider Allan Jonathan

Role GENERAL COUNSEL & CORP SEC

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	7,475	$0.00	--
Exercise	Restricted Stock Units	6,000	$0.00	--
Exercise	Restricted Stock Units	12,000	$0.00	--
Exercise	Common Stock	7,475	$0.00	--
Exercise	Common Stock	6,000	$0.00	--
Exercise	Common Stock	12,000	$0.00	--

Holdings After Transaction: Restricted Stock Units — 7,475 shares (Direct); Common Stock — 19,731 shares (Direct)

Footnotes (1)

1. The reported total includes an aggregate 425 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d). Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. The award vested or vests as to 1/4 of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the Issuer through each vesting date. The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2025, subject to the reporting person's continued service to the Issuer through each vesting date. The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the Issuer through each vesting date.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Allan Jonathan

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	GENERAL COUNSEL & CORP SEC

3. Date of Earliest Transaction (Month/Day/Year)
03/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/15/2026		M		7,475	A	$0	19,731(1)	D
Common Stock	03/15/2026		M		6,000	A	$0	25,731	D
Common Stock	03/15/2026		M		12,000	A	$0	37,731	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	03/15/2026		M			7,475	(3)	03/15/2027	Common Stock	7,475	$0	7,475	D
Restricted Stock Units	(2)	03/15/2026		M			6,000	(4)	03/15/2028	Common Stock	6,000	$0	12,000	D
Restricted Stock Units	(2)	03/15/2026		M			12,000	(5)	03/15/2029	Common Stock	12,000	$0	36,000	D

Explanation of Responses:

1. The reported total includes an aggregate 425 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d).

2. Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.

3. The award vested or vests as to 1/4 of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the Issuer through each vesting date.

4. The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2025, subject to the reporting person's continued service to the Issuer through each vesting date.

5. The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the Issuer through each vesting date.

	/s/ Jonathan Allan	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Stoke Therapeutics (STOK) report for Jonathan Allan?

Stoke Therapeutics reported that General Counsel Jonathan Allan exercised restricted stock units and acquired common shares. On March 15, 2026, he converted 25,475 RSUs into the same number of common shares at an exercise price of $0.00 per unit as part of equity compensation.

How many shares did Jonathan Allan acquire in the latest Stoke Therapeutics Form 4?

Jonathan Allan acquired 25,475 shares of Stoke Therapeutics common stock through RSU exercises. These derivative exercises converted previously granted RSUs into shares, increasing his directly held common stock position to 37,731 shares immediately following the reported transactions on March 15, 2026.

What type of securities did Jonathan Allan exercise at Stoke Therapeutics (STOK)?

He exercised restricted stock units, which are derivative equity awards. Each RSU represents a contingent right to receive one share of Stoke Therapeutics common stock upon settlement, so exercising 25,475 RSUs resulted in the issuance of 25,475 common shares at a $0.00 exercise price.

What vesting schedule applies to Jonathan Allan’s RSU awards at Stoke Therapeutics?

His RSU awards vest in annual installments over four years. One award vests 1/4 each year beginning March 15, 2024, a second beginning March 15, 2025, and a third beginning March 15, 2026, all conditioned on his continued service with Stoke Therapeutics through each vesting date.

How many Stoke Therapeutics shares does Jonathan Allan hold after the Form 4 transactions?

After the reported transactions, Jonathan Allan directly holds 37,731 shares of Stoke Therapeutics common stock. This total reflects the addition of 25,475 shares acquired through RSU exercises on March 15, 2026, as disclosed in the non-derivative transaction section.

Are Jonathan Allan’s recent Stoke Therapeutics transactions open-market buys or equity award exercises?

The transactions are equity award exercises, not open-market purchases. All reported entries use code “M” for exercises or conversions of derivative securities, specifically restricted stock units, with a $0.00 exercise price and no recorded open-market buying or selling activity.